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and Linda Sharp5
Abstract
Background: When individuals stop working due to cancer this represents a loss to society – the loss of productivity.
The aim of this analysis was to estimate productivity losses associated with premature mortality from all adult cancers
and from the 20 highest mortality adult cancers in Ireland in 2011, and project these losses until 2030.
Methods: An incidence-based method was used to estimate the cost of cancer deaths between 2011 and 2030 using
the Human Capital Approach. National data were used for cancer, population and economic inputs. Both paid work
and unpaid household activities were included. Sensitivity analyses estimated the impact of assumptions around future
cancer mortality rates, retirement ages, value of unpaid work, wage growth and discounting.
Results: The 233,000 projected deaths from all invasive cancers in Ireland between 2011 and 2030 will result in lost
productivity valued at €73 billion; €13 billion in paid work and €60 billion in household activities. These losses represent
approximately 1.4 % of Ireland’s GDP annually. The most costly cancers are lung (€14.4 billion), colorectal and breast
cancer (€8.3 billion each). However, when viewed as productivity losses per cancer death, testis (€364,000 per death),
cervix (€155,000 per death) and brain cancer (€136,000 per death) are most costly because they affect working age
individuals. An annual 1 % reduction in mortality reduces productivity losses due to all invasive cancers by €8.5 billion
over 20 years.
Conclusions: Society incurs substantial losses in productivity as a result of cancer-related mortality, particularly when
household production is included. These estimates provide valuable evidence to inform resource allocation decisions
in cancer prevention and control.
Keywords: Neoplasms, Cost of illness, Work, Employment, Labor force, Premature Mortality, Health care economics,
Productivity, Household activities, Human Capital Approach
Background
Over 40 % of those diagnosed with cancer in Europe are
of working age [1] and this proportion is increasing due
to a growing emphasis on early diagnosis, improved
treatment outcomes, and rising retirement ages [2].
When individuals exit the workforce temporarily or
permanently due to cancer, this represents a loss of
productivity for society. Similarly, productivity is also
lost when someone is unable to do unpaid production
tasks, such as housework, caring and volunteering.
These losses can be valued in monetary terms.
Together with measures of burden such as incidence
and mortality, estimates of cancer-related productivity loss
provide valuable evidence that can inform population-
based resource allocation decisions in cancer prevention
and control [3]. The patterns of cancer in society are
changing due to population ageing, early detection and
improved treatment [4] suggesting that the cancer burden,
irrespective of how it is measured, will change in coming
years. By projecting productivity losses into the future,
decision makers can account for these changes when allo-
cating resources.
Cancer mortality-related productivity losses have been
projected for the United States (US) from 2000–2020,
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and estimated that annual productivity lost due to can-
cer mortality would rise from USD$116 billion in 2000
to USD$148 in 2020 [5]. In Europe however, only single
year estimates are available [3, 6, 7]. Premature cancer-
related mortality in Ireland has been estimated to cost
€510 million annually [3]. While useful, these estimates
do not provide sufficient information to estimate the
potential economic savings of implementing cancer in-
terventions that impact future populations. In addition,
only two of these previous studies [3, 5] included unpaid
productivity, which approximately doubled the estimates
of lost productivity.
The aim of this study was to estimate national producti-
vity losses associated with premature mortality from all
adult cancers combined and from the 20 highest mortality
adult cancers in Ireland in 2011, and project these losses
until 2030.
Methods
Setting and approach
Ireland has a population of 4.6 million people [8], and
there are approximately 18,500 invasive cancers diag-
nosed in Ireland each year, and 8300 cancer deaths [9].
Over 45 % of those diagnosed with cancer in Ireland are
of working age (<65 years). Over the last 20 years, cancer
incidence has increased by approximately 3 % per year
due to population growth and aging [9], while cancer mor-
tality rates have declined by about 1 % per year [9]. Ireland
has a relatively young population, with approximately
66 % aged 15 to 64 years [10] and although participation
rates are somewhat below those in Europe, a rising pro-
portion of the population are in the workforce [11].
An incidence-based method was used to estimate the
cost of cancer deaths between 2011 and 2030. The
methods were based on those of Bradley et al. [5] and
used the Human Capital Approach, which measures lost
productivity as the time the working life is shortened
due to illness, valued at the market wage (or an equivalent
proxy). Both paid work (paid production) and unpaid
household activities (household production) were in-
cluded, consistent with methods recommended for the
societal perspective [12].
Data sources
Age specific cancer mortality data was provided by the
Central Statistics Office (CSO) and annual age-specific
cancer mortality rates by cancer site for all cancers com-
bined and the 20 most common cancers in terms of
deaths were calculated by the National Cancer Registry
Ireland. The CSO also provided national data for popu-
lation and economic inputs. These included: a) popula-
tion projections (using historical trends data) made in
2013 for 2016 to 2030, which assume a constant fertility
rate and slowing international immigration and emigration
[13]; b) projections (using historical trends data) of life ex-
pectancy between 2009 and 2030 [13]; c) annual earnings
in 2009, including basic earnings, bonuses and benefits in-
kind by gender and 10 year age group and averaged across
full- and part-time workers [14]; d) labour force participa-
tion and unemployment rates in 2011 by gender and
broad age groups (15–19, 20–24, then 10 year age groups
to 64) [15].
Time estimates for household production by gender
were obtained from the Organisation for Economic
Cooperation and Development (OECD) up to the age of
65 [16] and from the Time Use in Ireland Survey for
those aged over 65 [17]. Both surveys included routine
housework, care for household members, shopping,
volunteering and household related travel as household
production [16, 17], and the OECD also included caring
for non-household members. A proxy market wage for
all household production roles was assigned from the
public service pay scales of the Health Service Executive
(the public body in Ireland responsible for the provision
of health and personal social services), with ‘home help’
selected because it is a generalist role that could be
employed to complete any of the tasks included in our
definition of household production [18]. The OECD pro-
ject the average GDP growth rate from 2011 to 2030 as
2.1 % [19], which was used as a proxy for wage growth.
A discount rate of 5 % was used, as recommended for
Ireland [20].
Calculations
The number of cancer deaths annually between 2011
and 2030 was projected, by gender and five-year age
group, by applying the 2007 to 2011 average cancer-
specific annual mortality rate to the population projec-
tions for each year. The years lost until retirement for
each death were then calculated as the number of years
from the mid-point of the age group to the effective re-
tirement age (the average age of actual retirement, as
opposed to the official pensionable age) in Ireland:
64.6 years for males and 62.6 years for females [21].
Projected earnings were calculated accounting for wage
growth, unemployment rates and workforce participation
over the life course. For example, a 59 year old woman
who dies of cancer in 2020 had a base wage in 2020 of
€21,384, based on the 2010 base wage for women aged
50–59 plus 10 years of wage growth at 1.9 % (€41,409),
and adjusted for workforce participation (59.7 %) and un-
employment (13.5 %) rates of 50–59 year old women in
2020. For each year between diagnosis (age 59) and retire-
ment (age 62.6) a wage was calculated, accounting for
wage growth (1.9 %) from the previous year, and changes
in participation and unemployment rates based on the
increasing age of the individual. For example, in 2021
the woman would be 60 and have a probability of
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participation and unemployment of 48.9 % and 14.9 %
respectively, giving an average wage of €17,559.49; a
61 year old woman in 2022 would have another year of
wage growth, 48.9 % participation and 14.9 % unemploy-
ment and an average wage of €17,893.12, and so on. The
annual wages were then summed and adjusted for annual
discounting.
Household production was estimated for all cancer
deaths using a replacement cost approach - the hourly
rate to hire home help (€14.73/h) was multiplied by the
average number of hours spent in household production.
These costs were calculated from the age of cancer death
until life expectancy using the same approach described
for wages.
Results are presented as total costs and costs per
cancer death (by dividing the total cost by the number
of cancer deaths in the relevant age and gender groups),
and are given in 2011 Euros. All data management and
analyses were conducted in SAS 9.3.
Sensitivity analyses
Four scenarios were investigated in sensitivity analyses.
The first assumed a 1 % reduction each year in the num-
ber of cancer deaths per 100,000 (spread equally across
cancer types, age groups and genders), consistent with
conservative estimates of the trend in Ireland since 1994
[4]. The second varied the age of retirement, as Ireland
has relatively high rates of employment past pensionable
age [22]. Paid productivity losses were calculated to life
expectancy instead of effective retirement age, which
allows the proportion of individuals in Ireland who con-
tinue workforce participation after the pensionable age
of 65 (13.6 % of males and 5.1 % of females [15]) to be
included. The third used the age and gender specific
earnings to value unpaid household production, to take
an opportunity cost approach instead of a replacement
good approach. The fourth tested the impact of lower
wage growth (0 %), higher wage growth (3.5 %), lower
discounting (0 %) and higher discounting (6 %) on the
estimates.
Results
Deaths from all invasive adult cancers are projected to
increase annually in Ireland, with a total of over 233,000
deaths between 2011 and 2030. The total value of producti-
vity loss from these deaths is €73 billion - €13 billion in
paid production and €60 billion in household production.
Annual lost productivity rises from €2.3 billion in 2011
(€467 million paid production and €1.8 billion household
production) to €5.4 billion in 2030 (€811 million paid pro-
duction and €4.7 billion household production). Table 1
reports the paid production and household production
losses by cancer site in total and per cancer death.
The most costly cancers are lung (€14.4 billion), colorec-
tal and breast cancer (€8.3 billion each). Lung cancer results
in the highest paid productivity losses (€2.4 billion), which
is almost twice as costly as the next cancers – colorectal
and breast cancers (€1.3 billion each). The same can-
cers are most costly for household production: lung
(€12 billion), breast and colorectal (€7 billion each).
When viewed as paid production lost per cancer death,
the most costly cancers are testis (€364,000 per death),
cervix (€155,000 per death) and brain (€136,000 per
death). In contrast, for household production losses per
death the most costly cancers are cervix (€554,000 per
death), breast (€393,000 per death), and ovary (€367,000
per death).
Males account for 55 % of all invasive cancer deaths
between 2011 and 2030; 66 % of the total lost paid
production costs; and 42 % of the total lost household
production. This reflects gender-specific patterns in labour
force participation, wage rates, and household production.
Figures 1 and 2 display the results for each cancer by
gender, and the pattern of male dominated paid production
and female dominated household production is seen across
most sites.
Figures 3 and 4 displays lost production by age group
for five cancers: breast, brain and central nervous system,
colorectal, lung, and prostate. There is a large peak in the
55–59 age group, with a sharp decline after age 60.
Sensitivity analyses
The results of the sensitivity analyses are shown in
Tables 2, 3 and Fig. 5. A 1 % reduction in deaths per
100,000 in all invasive cancers reduces total productivity
loss to 88 % of the base case – a saving of €1.5 billion
for paid production and €7 billion for household pro-
duction (Table 2).
Assuming that some individuals continue working past
the effective retirement age results in a large increase in
paid productivity loss. For all invasive cancers between
2011 and 2030 the value of lost paid production is esti-
mated at €27 billion (212 % of the base case). Household
production was not affected, as this was not influenced
by retirement age in the base case.
Using age and gender specific wages to value house-
hold productivity resulted in a 32 % reduction in the
estimate of lost household productivity between 2011
and 2030. However, this was not consistent between
cancers, with corpus uteri reducing by 66 %, while testis
cancer increased by 117 % (Table 3).
Varying the growth and discount rates results in a
range of 71 % to 189 % (€9 to €24 billion) of the total
paid production losses for all invasive cancers, and a
range of 63 % to 259 % (€38 to €157 billion) of the total
household productivity losses for all invasive cancers.
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Table 1 Total losses due to cancer deaths 2011 – 2030, for all invasive cancers combined and by site (2011 Euros)
Cancer (ICD-10 code) Projected number of deaths Value of lost
paid production
(million €)
Value of lost
household production
(million €)
Value of lost
paid production
per death
Value of lost
household production
per death
C01-C14: mouth & pharynx 3691 €344 €954 €93,100 €258,363
C15: oesophagus 9928 €662 €2322 €66,653 €233,866
C16: stomach 9455 €603 €2265 €63,742 €239,541
C18-C21: colorectal 27,631 €1321 €6567 €47,818 €237,664
C22: liver 6641 €438 €1682 €65,998 €253,272
C25: pancreas 13,488 €733 €3355 €54,379 €248,753
C34: lung 48,922 €2403 €12,493 €49,116 €255,369
C43: melanoma skin 3698 €481 €1109 €129,992 €299,904
C44: non-melanoma skin 2297 €137 €492 €59,682 €214,112
C50: breast 18,308 €1255 €7194 €68,563 €392,941
C53: cervix 2200 €342 €1218 €155,238 €553,708
C54: corpus uteri 2104 €67 €706 €31,851 €335,495
C56: ovary 7150 €314 €2626 €43,859 €367,284
C61: prostate 17,012 €318 €2794 €18,667 €164,223
C62: testis 280 €102 €81 €364,187 €287,579
C64: kidney 5495 €413 €1374 €75,164 €250,066
C67: bladder 5929 €247 €1240 €41,734 €209,143
C70-C72: brain and CNS 6513 €886 €2164 €135,982 €332,348
C81-C85: lymphoma 7838 €528 €1989 €67,419 €253,744
C90: multiple myeloma 4380 €190 €1032 €43,319 €235,617
C91-C95: leukaemia 6693 €454 €1691 €67,773 €252,662
Other invasive cancers
not specified
25,558 €1373 €6282 €53,704 €245,775
C00-C96: all invasive cancers 233,168 €12,685 €60,427 €54,403 €259,155
Fig. 1 Projected value of lost paid production by gender
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Discussion
This analysis demonstrates the substantial productivity
loss incurred by society due to cancer-related premature
mortality - €73 billion in cumulative net present value in
Ireland over the next 20 years. To put these losses into
perspective, they represent approximately 1.4 % of Ireland’s
gross domestic product (GDP; €159 billion) annually [23].
These projections can inform investment decisions at a
time of aging populations, increasing cancer incidence and
later retirement.
It is difficult to compare these results with previous
estimates due to differing approaches and assumptions.
Our results for 2012 are similar to or lower than previous
single year estimates of total paid productivity losses due
to cancer in Europe (including Ireland) [3, 6, 7]. This may
be explained by our use of effective retirement age rather
than pensionable age as a cut off for lost paid production,
and our higher discount rate (5 % in our study compared
to 3.5 % [6, 7] or 4 % [3] in other studies). In contrast, our
estimates of productivity loss per cancer death are lower
Fig. 2 Projected value of lost household production by gender
Fig. 3 Projected value of lost paid production by age group
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than seen in a US study of projected cancer mortality
costs 2000 to 2020 [5], likely due to differences in settings
such as the US having higher wage rates (14 % higher than
Ireland [24]), later retirement and higher workforce par-
ticipation rates [5].
Despite any differences in magnitude, the spread of
lost productivity across different cancer sites in our re-
sults is very similar to those seen in previous studies
[3, 5–7]. For paid productivity losses, cancers with high
incidence in working age individuals, such as colorectal
and lung cancer, are most costly overall. When cost per
death is considered, cancers that occur in younger people,
like testis, brain and cervical cancer, incur higher costs
despite lower incidence because of the additional potential
productive years of life lost. These two outcomes provide
complementary perspectives for informing cancer control
activities. When taken into consideration along with inci-
dence and mortality, lost productivity estimates suggest
that investment in a range of interventions, including
some which target working age people, is important.
The results of this analysis can also be compared to
cost of illness studies in other diseases in Ireland. The
annual lost paid productivity due to premature mortality
in this study is almost double that of both cardiovascular
disease [25] and suicide [26], nearly seven times that of
schizophrenia [27], and over 155 times that of dementia
[28]. These results highlight the relative impact of cancer
on the economy, and allow public policy to take a broader
perspective on healthcare planning and prioritisation.
While higher paid productivity losses were seen for men
within the analysis, these are due to higher wages and
workforce participation rates in males. These differences
are therefore driven by economic factors, rather than
by value.
The inclusion of household production offers a coun-
terbalance to estimations based on wage alone, which
Fig. 4 Projected value of lost household production by age group
Table 2 Sensitivity analysis – reductions in mortality by 1 % per year for specified cancers
Cancer Projected number
of deaths
Value of lost
paid production
(million €)
Value of lost
household production
(million €)
Projected number of
deaths (% of base case)
Value of lost
paid production
(million €)
Value of lost
household production
(million €)
Base case 1 % Annual reduction in mortality
C18-C21: colorectal 27,631 1321 6567 23,344 (84 %) 1169 5765
C25: pancreas 13,488 733 3355 11,673 (87 %) 649 2947
C34: lung 48,922 2403 12,493 41,730 (85 %) 2124 10,970
C50: breast 18,308 1255 7194 15,430 (84 %) 1113 6338
C70-C72: brain &
CNS
6513 886 2164 5265 (81 %) 786 1907
C91-C95: leukaemia 6693 454 1691 5096 (76 %) 402 1486
C00-C96: all invasive 233,168 12,685 60,427 206,336 (89 %) 11,231 53,086
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often undervalues contributions of women and younger
and older workers who have reduced paid workforce
participation. Household production is rarely included
in estimates of disease burden in Europe [29], which re-
sults in an underestimation of the burden incurred by
society. However, this study shows these losses are
substantial – between three and five times the losses
due to paid production, depending on the method of
valuation (opportunity cost or replacement cost). Studies
that include household production often do not give a
breakdown of paid and household production [30–33]. A
study in the US used a narrower definition of household
Table 3 Sensitivity analysis – using opportunity cost value of household production, instead of replacement cost
Cancer Total lost household productivity
(base case)
Total lost household productivity
(opportunity cost)
% of base case
(Million €) (Million €) %
C01-C14: mouth & pharynx €954 €975 102
C15: oesophagus €2322 €2067 89
C16: stomach €2265 €1824 81
C18-C21: colorectal €6567 €4571 70
C22: liver €1682 €1330 79
C25: pancreas €3355 €2392 71
C34: lung €12,493 €8730 70
C43: melanoma skin €1109 €1096 99
C44: non-melanoma skin €492 €374 76
C50: breast €7194 €3444 48
C53: cervix €1218 €763 63
C54: corpus uteri €706 €239 34
C56: ovary €2626 €987 38
C61: prostate €2794 €1911 68
C62: testis €81 €175 217
C64: kidney €1374 €1228 89
C67: bladder €1240 €830 67
C70-C72: brain and CNS €2164 €2129 98
C81-C85: lymphoma (total) €1989 €1483 75
C90: multiple myeloma €1032 €670 65
C91-C95: leukaemia (total) €1691 €1267 75
Other invasive cancers bar specified €6282 €4286 68
C00-C96: all invasive cancer deaths €60,427 €41,286 68
Fig. 5 Sensitivity Analyses – All invasive cancer results for paid and household production as a percentage of the base case
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production (including only housework and caring) and
found household productivity losses to be approximately
double those of paid production [5].
The sensitivity analysis demonstrates the impact of
various assumptions within the analysis. Over the last
20 years cancer mortality has reduced in Ireland and
worldwide by between 1 % and 2 % annually (averaged
across all cancer types, age groups and genders) through
improved screening and earlier detection, improved diet,
improved treatments and reduced tobacco use [34]. The
impact on productivity losses of continuing this trend
provides a strong argument for economies to invest in
strategies to reduce cancer mortality, as despite dis-
counting within the calculations giving initial years more
weight, the increasing population results in ongoing
savings throughout the period.
In addition to improved treatments, an ongoing reduc-
tion in cancer mortality in Ireland may be achieved
through other mechanisms [34]. Smoking rates in Ireland
remain higher than in other countries, but are declining
[35]. Given the number of cancers in which smoking is
aetiologically implicated [36], and growing evidence of
smoking as a prognostic factor [37], implementation of
further initiatives to support smoking cessation (and
reduce uptake) could yield significant economic benefits.
National breast cancer screening is relatively new in
Ireland, so the full benefits have not yet been realized [38].
A new screening programme for colorectal cancer has
recently been introduced [39] and there is potential for
spiral CT to be used for high risk lung cancer screening
[40]. The HPV vaccine, provided to girls through a schools
based programme, has high uptake in Ireland and should
have a significant impact on cervical cancer rates in the
future, particularly if extended to boys [41]. Finally, redu-
cing inequalities in cancer diagnosis, management and
prevention for those in lower socioeconomic groups, with
lower education levels, or with comorbidities could signifi-
cantly improve cancer mortality [34, 42].
The age of retirement makes a large difference in the
estimates, with increasing workforce participation after
retirement age increasing productivity loss by €14 billion.
Ireland has a relatively high proportion of workers over re-
tirement age, perhaps related to the high level of farming
activity in the country. Given the potential for retirement
ages to rise further in the future, the base case assumption
are likely an underestimate of the true loss [22].
One of the unique aspects of this study is the projection
of productivity losses into the future. This is particularly
useful for diseases, such as cancer, where prevention is a
key component of control. Typical assessments of disease
burden discount avoidable costs in the future. Estimating
future productivity loss draws specific attention to the im-
portance of prevention, to inform the healthcare resource
allocation debate.
While these future projections are important, they are
also based on assumptions of the population in the
future [13], which are inherently uncertain. In Ireland,
migration is the most influential factor in determining
population change, and is subject to significant fluctua-
tions [13]. High migration together with substantial un-
employment at present in Ireland means the Human
Capital Approach may underestimate the future burden on
society, however the message regarding relative, as well as
the absolute, costs across cancers and activities remains
important. Similarly, recent research suggests the increased
levels of unemployment seen following the economic crisis
in 2008 were associated with an increase in cancer mor-
tality [43], which has not been accounted for in our
mortality projections, and could mean our estimates
provide a lower bound of the true magnitude of lost
productivity due to cancer-related premature mortality.
The use of a 1 % mortality reduction across all cancers,
rather than trends specific for certain cancer types is
somewhat crude and there is an opportunity for future re-
search to use detailed data to project changes in mortality
for individual cancers. For example, screening programs
have had clear impacts on the incidence (and possibly
mortality) of breast, prostate and cervical cancers in
Ireland [9]. The recent introduction of a colorectal cancer
screening program, which includes people of working age
in the target population [39], and the human papilloma
virus vaccine targeting cervical cancer [44], could both
result in reduced productivity loss into the future, on top
of the typical measures of impact such as incidence.
A further limitation is that this analysis is limited to
productivity losses resulting from premature mortality.
Other forms of productivity loss, such as temporary
workplace absence or early retirement, the costs associ-
ated with cancer detection and treatment, the costs to
family members or the impact on quality of life are not
captured, largely due to a lack of data. These all contribute
to the financial toxicity of cancer, and the ongoing im-
provements in cancer mortality mean services such as
financial planning and employment rehabilitation are
increasingly essential components of treatment.
Conclusion
Cancer mortality will result in €73 billion in productivity
losses in Ireland from 2011 to 2030, 83 % of which is
due to lost household production. These losses represent
approximately 1.4 % of Ireland’s GDP annually. These
results highlight that while reducing incidence and mor-
tality of high incidence cancers is important, so too are
interventions and policies to reduce lower incidence
cancers, which disproportionately impact working age
individuals. These estimates provide valuable evidence to
policy makers regarding resource allocation decisions for
cancer prevention and control.
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